Revisiting: Absolute versus relative contraindications — setting out what I have, and where I think it stops being reliable.
A narrow question about Absolute versus relative contraindications, deliberately narrow, because the broad version has been asked here four times and produced four long threads and no answer.
One question, stated units, stated method, and what I have already ruled out.
Reading rather than contributing, but this is the most useful thread I have found on it.
Post #3 is right about the mechanism and I think understates the practical bit.
Somebody's condition being on a list does not settle the decision, and somebody's condition being absent from one does not either.
Where a contraindication is relative rather than absolute, the reasoning usually appears in the assessment report rather than the labelling.
I would not lead a decision with this, but I would not ignore it either.
Post #6 answers the question as asked. The question underneath it is different.
Allergy to the specific compound: true allergy is rare but possible. Any prior allergic reaction to the same compound or to structurally similar peptides warrants caution.
Adding it because I spent an afternoon working it out and nobody should have to twice.
The section of the product information covering special warnings is usually longer and more useful than the contraindications list itself.
This follows post #8 rather than contradicting it.
I have no financial interest in anything named in this thread and I want to say so before I comment on Absolute versus relative contraindications, because it is the sort of subject where it matters.
This follows post #8 rather than contradicting it.
I disagree with the framing of Absolute versus relative contraindications above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.
The reasoning depends on an assumption that is doing a lot of work and is never stated. If the assumption holds, the conclusion follows. I do not think it holds generally.
That matches what I have seen, for whatever a single anecdote is worth.
Medullary thyroid carcinoma (personal or family history) or multiple endocrine neoplasia type 2: absolute contraindication. The rodent preclinical signal is real enough to exclude this population.
The evidence for this is thinner than the way I have phrased it suggests.
Disordered eating history: appetite suppression can trigger relapse in people with history of anorexia, bulimia, or other eating disorders. This is a relative contraindication requiring specialist input.
It is the sort of thing that seems obvious in retrospect and was not at the time.
That is clearer than the version I had in my head. Thank you.
Coming back to post #14, because the follow-up matters more than the original answer.
Two things can be true about Absolute versus relative contraindications at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is people defending the first against attacks on the second.
History of pancreatitis: these compounds can rarely trigger pancreatitis. History of pancreatitis increases relative risk. That is a relative contraindication, not absolute, but requires monitoring.
A modest claim, modestly supported.
Gastroparesis or severe delayed gastric emptying: these compounds slow gastric emptying. Pre-existing severe gastroparesis can be worsened. That is a relative contraindication depending on baseline severity.
I would treat the number as indicative rather than as a measurement.
Reading the contraindications section of the actual product information takes two minutes and answers most questions asked here.
This follows post #19 rather than contradicting it.
Two people in this thread mean different things by Absolute versus relative contraindications and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.
Allergy to the specific compound: true allergy is rare but possible. Any prior allergic reaction to the same compound or to structurally similar peptides warrants caution.
Picking up post #24: that is the part I would want checked first.
Marking my uncertainty on Absolute versus relative contraindications explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past the case in the first post.
Taking Absolute versus relative contraindications seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences.
Research-use-only material has no labelling and therefore no contraindications listed, which is not the same as having none.
That is the practical version. The rigorous version is longer and says the same thing.
I would call the community position on Absolute versus relative contraindications likely rather than established, and I would be comfortable defending that hedge.